CEO
Beth Rogozinski is CEO of Oncoustics, an innovative AI solutions company that is creating low cost, non-invasive surveillance, diagnostics, and treatment monitoring for diseases with high unmet clinical need. Beth spent the last 15 years focused on digital medicine and health innovations, producing and publishing over a dozen software as a medical device solutions and applications. As Chief Product Officer at Pear Therapeutics, Beth led the development of Pear’s first clinical products and the product team’s submission to the FDA. Pear’s ReSET™ was FDA-cleared in 2017 as the first prescription digital therapeutic. Beth is a board director or advisor to many health innovation companies, has guest lectured at UCSF, Columbia, and Northwestern, and serves on BIO’s educational committees. She has written and published on digital medicine and health-tech innovations and is a frequent speaker at technology and healthcare events.